Immunotech Laboratories, Inc. (IMMB)
OTCMKTS
· Delayed Price · Currency is USD
0.0002
+0.0001 (100.00%)
At close: Feb 18, 2026
Immunotech Laboratories Company Description
Immunotech Laboratories, Inc. develops and commercializes proprietary proteins for use in treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders.
Its flagship compound is ITV-1 (immune therapeutic vaccine), a suspension of irreversible pepsin fraction that is used in the treatment of HIV/AIDS and Hepatitis C, as well as to modulate the immune system.
The company is headquartered in Monrovia, California. As of June 14, 2017, Immunotech Laboratories, Inc. operates as a subsidiary of Enzolytics, Inc.
Immunotech Laboratories, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
Contact Details
Address: 120 West Pomona Avenue Monrovia, California 91016 United States | |
| Phone | 626-538-4779 |
| Website | immunotechlab.com |
Stock Details
| Ticker Symbol | IMMB |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US45254F2039 |
| SIC Code | 7812 |
Key Executives
| Name | Position |
|---|---|
| Harry H. Zhabilov Jr., BSc, McS Science | Founder, Vice Chairman, President, Chief Science Officer and Secretary |
| Billy Ray | Chief Financial Officer, Executive of Business and Development and Member of Advisory Board |
| Adam S. Tracy Esq., J.D., MBA | Legal Counsel |